 Nanette Santoro
Concepts (960)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Menopause | 106 | 2026 | 326 | 21.540 |
Why?
| | Hot Flashes | 40 | 2025 | 92 | 10.420 |
Why?
| | Infertility, Female | 47 | 2024 | 122 | 7.980 |
Why?
| | Estrogen Replacement Therapy | 37 | 2026 | 143 | 7.640 |
Why?
| | Menstrual Cycle | 41 | 2026 | 145 | 6.400 |
Why?
| | Women's Health | 44 | 2026 | 316 | 6.120 |
Why?
| | Perimenopause | 26 | 2025 | 69 | 6.080 |
Why?
| | Follicle Stimulating Hormone | 66 | 2026 | 266 | 5.600 |
Why?
| | Estradiol | 62 | 2026 | 515 | 5.560 |
Why?
| | Polycystic Ovary Syndrome | 36 | 2026 | 188 | 5.470 |
Why?
| | Luteinizing Hormone | 59 | 2026 | 207 | 5.220 |
Why?
| | Ovary | 28 | 2025 | 234 | 5.050 |
Why?
| | Endocrinology | 9 | 2023 | 77 | 4.350 |
Why?
| | Postmenopause | 38 | 2026 | 394 | 4.250 |
Why?
| | Metabolic Syndrome | 17 | 2026 | 361 | 3.740 |
Why?
| | Progesterone | 40 | 2026 | 215 | 3.710 |
Why?
| | Anti-Mullerian Hormone | 16 | 2023 | 61 | 3.590 |
Why?
| | Infertility | 13 | 2024 | 61 | 3.480 |
Why?
| | Reproductive Medicine | 8 | 2023 | 18 | 3.290 |
Why?
| | Live Birth | 23 | 2024 | 81 | 3.250 |
Why?
| | Estrogens | 26 | 2026 | 367 | 3.250 |
Why?
| | Female | 371 | 2026 | 79045 | 3.130 |
Why?
| | Receptors, Neurokinin-3 | 5 | 2025 | 8 | 2.740 |
Why?
| | Ovulation Induction | 30 | 2024 | 65 | 2.680 |
Why?
| | Fertilization in Vitro | 20 | 2026 | 108 | 2.670 |
Why?
| | Obesity | 33 | 2024 | 3118 | 2.640 |
Why?
| | Primary Ovarian Insufficiency | 14 | 2021 | 40 | 2.630 |
Why?
| | Fertility | 16 | 2024 | 174 | 2.620 |
Why?
| | Humans | 393 | 2026 | 145785 | 2.490 |
Why?
| | Vasomotor System | 11 | 2025 | 47 | 2.470 |
Why?
| | Hormones | 13 | 2021 | 135 | 2.410 |
Why?
| | Androgens | 15 | 2021 | 181 | 2.370 |
Why?
| | Diet, High-Fat | 3 | 2026 | 266 | 2.310 |
Why?
| | Luteal Phase | 16 | 2020 | 51 | 2.280 |
Why?
| | Gonadal Steroid Hormones | 16 | 2026 | 143 | 2.250 |
Why?
| | Reproduction | 9 | 2022 | 208 | 2.110 |
Why?
| | Aging | 30 | 2025 | 1973 | 2.060 |
Why?
| | Adult | 204 | 2026 | 40882 | 2.060 |
Why?
| | Estrogens, Conjugated (USP) | 16 | 2026 | 52 | 2.020 |
Why?
| | Heterocyclic Compounds, 2-Ring | 8 | 2024 | 18 | 1.990 |
Why?
| | Biomarkers | 36 | 2025 | 4302 | 1.940 |
Why?
| | Ovarian Follicle | 11 | 2025 | 78 | 1.850 |
Why?
| | Thiadiazoles | 8 | 2024 | 25 | 1.830 |
Why?
| | Pregnanediol | 14 | 2026 | 23 | 1.800 |
Why?
| | Cryopreservation | 6 | 2024 | 113 | 1.750 |
Why?
| | Endometrium | 15 | 2020 | 64 | 1.740 |
Why?
| | Ovulation | 14 | 2018 | 46 | 1.690 |
Why?
| | Depression | 13 | 2024 | 1559 | 1.690 |
Why?
| | Fertility Agents, Female | 14 | 2022 | 23 | 1.650 |
Why?
| | Testosterone | 24 | 2021 | 416 | 1.630 |
Why?
| | Menopause, Premature | 4 | 2021 | 12 | 1.620 |
Why?
| | Pregnancy | 74 | 2026 | 7216 | 1.610 |
Why?
| | Pregnancy Rate | 22 | 2024 | 81 | 1.540 |
Why?
| | Cardiovascular Diseases | 24 | 2026 | 2191 | 1.530 |
Why?
| | Hypothalamo-Hypophyseal System | 6 | 2024 | 199 | 1.480 |
Why?
| | Double-Blind Method | 35 | 2025 | 2064 | 1.480 |
Why?
| | Hormone Replacement Therapy | 9 | 2022 | 107 | 1.450 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2024 | 154 | 1.440 |
Why?
| | Quality of Life | 19 | 2026 | 3211 | 1.430 |
Why?
| | Sexual Dysfunction, Physiological | 9 | 2018 | 75 | 1.430 |
Why?
| | Longevity | 2 | 2025 | 178 | 1.400 |
Why?
| | Estrone | 12 | 2026 | 41 | 1.390 |
Why?
| | Infertility, Male | 11 | 2022 | 80 | 1.370 |
Why?
| | Middle Aged | 132 | 2026 | 36309 | 1.340 |
Why?
| | Carotid Intima-Media Thickness | 10 | 2021 | 75 | 1.320 |
Why?
| | Mental Health | 3 | 2024 | 796 | 1.310 |
Why?
| | Premenopause | 14 | 2022 | 125 | 1.260 |
Why?
| | Body Mass Index | 35 | 2026 | 2447 | 1.240 |
Why?
| | Amenorrhea | 12 | 2017 | 31 | 1.230 |
Why?
| | Gonadotropin-Releasing Hormone | 16 | 2022 | 217 | 1.200 |
Why?
| | Sleep Wake Disorders | 8 | 2026 | 314 | 1.190 |
Why?
| | Vaginal Diseases | 3 | 2020 | 19 | 1.160 |
Why?
| | Vagina | 3 | 2020 | 203 | 1.160 |
Why?
| | Endocrinologists | 3 | 2023 | 12 | 1.150 |
Why?
| | Hypothalamus | 10 | 2014 | 163 | 1.130 |
Why?
| | Hormone Antagonists | 2 | 2021 | 33 | 1.090 |
Why?
| | Inhibins | 8 | 2018 | 41 | 1.080 |
Why?
| | Pregnancy Outcome | 11 | 2024 | 504 | 1.060 |
Why?
| | Gynecology | 2 | 2021 | 181 | 1.060 |
Why?
| | Embryo Transfer | 10 | 2024 | 45 | 1.050 |
Why?
| | Atherosclerosis | 6 | 2024 | 409 | 1.040 |
Why?
| | Prospective Studies | 47 | 2025 | 8078 | 1.020 |
Why?
| | Endometriosis | 4 | 2022 | 58 | 0.990 |
Why?
| | Anovulation | 7 | 2015 | 9 | 0.990 |
Why?
| | Hyperlipidemias | 5 | 2022 | 120 | 0.980 |
Why?
| | Uterus | 4 | 2019 | 228 | 0.940 |
Why?
| | Randomized Controlled Trials as Topic | 20 | 2024 | 1752 | 0.920 |
Why?
| | Young Adult | 38 | 2026 | 14254 | 0.920 |
Why?
| | Hyperinsulinism | 3 | 2022 | 115 | 0.900 |
Why?
| | Clomiphene | 9 | 2021 | 16 | 0.900 |
Why?
| | Treatment Outcome | 40 | 2024 | 11794 | 0.890 |
Why?
| | Sex Hormone-Binding Globulin | 15 | 2025 | 52 | 0.890 |
Why?
| | Patient Selection | 7 | 2021 | 739 | 0.870 |
Why?
| | Insulin Resistance | 11 | 2025 | 1244 | 0.870 |
Why?
| | Aromatase Inhibitors | 3 | 2020 | 81 | 0.850 |
Why?
| | Insulin | 12 | 2025 | 2516 | 0.840 |
Why?
| | Preconception Care | 2 | 2024 | 50 | 0.830 |
Why?
| | Follicle Stimulating Hormone, Human | 3 | 2022 | 14 | 0.820 |
Why?
| | Adipose Tissue | 4 | 2024 | 645 | 0.810 |
Why?
| | Adipokines | 1 | 2024 | 57 | 0.810 |
Why?
| | Fertility Preservation | 1 | 2024 | 55 | 0.810 |
Why?
| | United States | 52 | 2026 | 16126 | 0.800 |
Why?
| | Salpingo-oophorectomy | 1 | 2024 | 19 | 0.800 |
Why?
| | Life Cycle Stages | 1 | 2023 | 37 | 0.800 |
Why?
| | Glucose Tolerance Test | 2 | 2024 | 361 | 0.790 |
Why?
| | Biomedical Research | 4 | 2023 | 719 | 0.780 |
Why?
| | Menarche | 2 | 2017 | 53 | 0.780 |
Why?
| | Hypogonadism | 9 | 2024 | 93 | 0.770 |
Why?
| | Longitudinal Studies | 26 | 2026 | 2968 | 0.770 |
Why?
| | HIV Infections | 17 | 2024 | 3195 | 0.760 |
Why?
| | Gonadotropins | 5 | 2020 | 44 | 0.760 |
Why?
| | Weight Loss | 6 | 2024 | 859 | 0.750 |
Why?
| | Progestins | 4 | 2017 | 66 | 0.750 |
Why?
| | Aromatase | 3 | 2014 | 37 | 0.750 |
Why?
| | Administration, Cutaneous | 13 | 2026 | 127 | 0.730 |
Why?
| | Irritable Mood | 3 | 2018 | 50 | 0.730 |
Why?
| | Body Composition | 11 | 2025 | 693 | 0.730 |
Why?
| | Ovarian Reserve | 3 | 2020 | 18 | 0.720 |
Why?
| | Corpus Luteum | 8 | 2017 | 23 | 0.720 |
Why?
| | Drug Compounding | 3 | 2021 | 107 | 0.720 |
Why?
| | Pituitary Gland | 6 | 2021 | 149 | 0.720 |
Why?
| | Leiomyoma | 5 | 2025 | 61 | 0.710 |
Why?
| | Cytokines | 4 | 2024 | 2069 | 0.710 |
Why?
| | Sexual Health | 1 | 2023 | 68 | 0.700 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2021 | 1420 | 0.690 |
Why?
| | Risk Factors | 49 | 2024 | 10919 | 0.680 |
Why?
| | Research Subjects | 1 | 2021 | 41 | 0.670 |
Why?
| | Abortion, Spontaneous | 8 | 2024 | 119 | 0.670 |
Why?
| | Fetal Research | 1 | 2021 | 3 | 0.670 |
Why?
| | Soybean Oil | 1 | 2021 | 15 | 0.670 |
Why?
| | Embryo, Mammalian | 1 | 2022 | 234 | 0.670 |
Why?
| | Federal Government | 1 | 2021 | 23 | 0.670 |
Why?
| | Age Factors | 22 | 2023 | 3346 | 0.660 |
Why?
| | Lipids | 7 | 2023 | 707 | 0.660 |
Why?
| | Hydrocortisone | 4 | 2022 | 298 | 0.660 |
Why?
| | Cohort Studies | 30 | 2024 | 6033 | 0.660 |
Why?
| | Bicycling | 1 | 2021 | 117 | 0.650 |
Why?
| | Hand Strength | 1 | 2021 | 144 | 0.640 |
Why?
| | Sleep Initiation and Maintenance Disorders | 4 | 2018 | 196 | 0.640 |
Why?
| | Pregnancy Complications | 3 | 2024 | 603 | 0.640 |
Why?
| | Adolescent | 49 | 2024 | 22577 | 0.630 |
Why?
| | Symptom Assessment | 2 | 2021 | 136 | 0.630 |
Why?
| | Adiposity | 5 | 2026 | 532 | 0.630 |
Why?
| | Premature Birth | 4 | 2024 | 390 | 0.620 |
Why?
| | Cross-Sectional Studies | 31 | 2026 | 5925 | 0.610 |
Why?
| | Ultrasonography | 6 | 2018 | 788 | 0.610 |
Why?
| | Reproductive Health | 3 | 2023 | 91 | 0.600 |
Why?
| | Phospholipids | 1 | 2021 | 214 | 0.600 |
Why?
| | Obstetrics | 1 | 2021 | 177 | 0.590 |
Why?
| | Feasibility Studies | 1 | 2024 | 1115 | 0.590 |
Why?
| | Practice Guidelines as Topic | 3 | 2016 | 1582 | 0.570 |
Why?
| | Spatial Memory | 1 | 2019 | 27 | 0.570 |
Why?
| | Hysterosalpingography | 1 | 2018 | 9 | 0.560 |
Why?
| | Sexuality | 1 | 2018 | 32 | 0.560 |
Why?
| | Hypothalamic Diseases | 3 | 2017 | 17 | 0.560 |
Why?
| | Cognition | 11 | 2026 | 1271 | 0.560 |
Why?
| | Sleep | 9 | 2021 | 889 | 0.560 |
Why?
| | Ovarian Hyperstimulation Syndrome | 3 | 2008 | 6 | 0.560 |
Why?
| | Liver | 4 | 2024 | 1899 | 0.550 |
Why?
| | Menstruation | 10 | 2024 | 40 | 0.540 |
Why?
| | Thyrotropin | 4 | 2024 | 120 | 0.540 |
Why?
| | Life Style | 10 | 2024 | 486 | 0.530 |
Why?
| | Phenotype | 5 | 2024 | 3170 | 0.520 |
Why?
| | Chorionic Gonadotropin | 10 | 2024 | 78 | 0.520 |
Why?
| | Anxiety | 5 | 2024 | 1122 | 0.520 |
Why?
| | Insemination, Artificial | 5 | 2022 | 12 | 0.520 |
Why?
| | Abortifacient Agents, Nonsteroidal | 3 | 2024 | 20 | 0.520 |
Why?
| | Methotrexate | 5 | 2024 | 233 | 0.500 |
Why?
| | Watchful Waiting | 3 | 2024 | 90 | 0.490 |
Why?
| | Hyperandrogenism | 5 | 2024 | 25 | 0.490 |
Why?
| | Hypopituitarism | 2 | 2014 | 16 | 0.490 |
Why?
| | Health Surveys | 5 | 2011 | 520 | 0.490 |
Why?
| | Military Personnel | 1 | 2024 | 739 | 0.480 |
Why?
| | Hysterectomy | 5 | 2023 | 138 | 0.480 |
Why?
| | Fetus | 1 | 2021 | 804 | 0.480 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2011 | 297 | 0.470 |
Why?
| | Pregnancy Trimester, First | 2 | 2019 | 139 | 0.470 |
Why?
| | Substance-Related Disorders | 6 | 2009 | 1103 | 0.470 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2016 | 34 | 0.470 |
Why?
| | Cumulus Cells | 2 | 2015 | 7 | 0.460 |
Why?
| | Levonorgestrel | 1 | 2015 | 34 | 0.450 |
Why?
| | Sweating | 4 | 2018 | 43 | 0.450 |
Why?
| | Uterine Hemorrhage | 3 | 2021 | 41 | 0.450 |
Why?
| | Insemination, Artificial, Heterologous | 1 | 2015 | 2 | 0.450 |
Why?
| | Circadian Rhythm | 3 | 2017 | 513 | 0.440 |
Why?
| | Azoospermia | 1 | 2015 | 10 | 0.440 |
Why?
| | Overweight | 5 | 2014 | 614 | 0.440 |
Why?
| | Surveys and Questionnaires | 20 | 2022 | 6085 | 0.420 |
Why?
| | Bone Density | 7 | 2011 | 487 | 0.420 |
Why?
| | Tandem Mass Spectrometry | 2 | 2015 | 572 | 0.420 |
Why?
| | Pulsatile Flow | 3 | 2011 | 61 | 0.420 |
Why?
| | Time Factors | 21 | 2025 | 7134 | 0.420 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 109 | 0.420 |
Why?
| | Vulvodynia | 1 | 2014 | 2 | 0.420 |
Why?
| | Granulosa Cells | 4 | 2021 | 37 | 0.410 |
Why?
| | Blood Proteins | 1 | 2015 | 239 | 0.400 |
Why?
| | Nitriles | 5 | 2015 | 211 | 0.400 |
Why?
| | Triazoles | 5 | 2015 | 191 | 0.390 |
Why?
| | Osteoporosis | 1 | 2016 | 239 | 0.380 |
Why?
| | Obesity, Abdominal | 3 | 2026 | 47 | 0.380 |
Why?
| | Follow-Up Studies | 18 | 2025 | 5428 | 0.380 |
Why?
| | Pregnancy, Multiple | 4 | 2015 | 19 | 0.380 |
Why?
| | White Matter | 2 | 2025 | 155 | 0.380 |
Why?
| | Pregnancy, Ectopic | 4 | 2024 | 54 | 0.380 |
Why?
| | Cross-Over Studies | 4 | 2022 | 610 | 0.380 |
Why?
| | Solubility | 2 | 2023 | 240 | 0.370 |
Why?
| | Uterine Neoplasms | 3 | 2025 | 98 | 0.360 |
Why?
| | Parity | 2 | 2011 | 111 | 0.360 |
Why?
| | Insemination, Artificial, Homologous | 3 | 2021 | 3 | 0.360 |
Why?
| | Prevalence | 14 | 2025 | 2875 | 0.360 |
Why?
| | Follicular Phase | 12 | 2014 | 41 | 0.360 |
Why?
| | Indoles | 1 | 2016 | 507 | 0.360 |
Why?
| | Complementary Therapies | 3 | 2022 | 96 | 0.360 |
Why?
| | Male | 65 | 2024 | 73012 | 0.350 |
Why?
| | Prolactin | 4 | 2022 | 87 | 0.350 |
Why?
| | Stress, Psychological | 8 | 2018 | 1151 | 0.350 |
Why?
| | Cell Cycle | 1 | 2015 | 598 | 0.350 |
Why?
| | Human Growth Hormone | 2 | 2022 | 47 | 0.340 |
Why?
| | Plaque, Atherosclerotic | 2 | 2024 | 61 | 0.340 |
Why?
| | Intracranial Thrombosis | 1 | 2011 | 19 | 0.340 |
Why?
| | Aged | 26 | 2025 | 26217 | 0.340 |
Why?
| | Fallopian Tubes | 3 | 2018 | 33 | 0.340 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2008 | 279 | 0.330 |
Why?
| | Endocrine System | 1 | 2011 | 22 | 0.330 |
Why?
| | Weight Gain | 5 | 2020 | 561 | 0.320 |
Why?
| | Uterine Diseases | 2 | 2007 | 18 | 0.320 |
Why?
| | Inflammation | 4 | 2024 | 2885 | 0.310 |
Why?
| | Coronary Artery Disease | 4 | 2019 | 750 | 0.310 |
Why?
| | Logistic Models | 14 | 2015 | 2139 | 0.310 |
Why?
| | Activins | 3 | 2005 | 29 | 0.300 |
Why?
| | Regression Analysis | 7 | 2020 | 1001 | 0.300 |
Why?
| | Reproductive Techniques, Assisted | 3 | 2021 | 47 | 0.300 |
Why?
| | Prognosis | 15 | 2020 | 4330 | 0.300 |
Why?
| | Odds Ratio | 14 | 2015 | 1083 | 0.300 |
Why?
| | Diabetes Mellitus | 4 | 2025 | 1101 | 0.300 |
Why?
| | Oocyte Donation | 1 | 2009 | 6 | 0.290 |
Why?
| | Vulva | 1 | 2009 | 24 | 0.290 |
Why?
| | Trinucleotide Repeats | 1 | 2009 | 31 | 0.290 |
Why?
| | Exercise | 3 | 2022 | 2205 | 0.290 |
Why?
| | Multivariate Analysis | 13 | 2015 | 1547 | 0.290 |
Why?
| | Lactation | 2 | 2024 | 193 | 0.290 |
Why?
| | Fertility Agents | 2 | 2020 | 3 | 0.290 |
Why?
| | Luteal Cells | 1 | 2008 | 3 | 0.290 |
Why?
| | Incidence | 9 | 2025 | 2934 | 0.280 |
Why?
| | Semen | 4 | 2022 | 24 | 0.280 |
Why?
| | Administration, Oral | 8 | 2020 | 867 | 0.280 |
Why?
| | Pituitary Hormone-Releasing Hormones | 6 | 1989 | 10 | 0.280 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 740 | 0.280 |
Why?
| | Multicenter Studies as Topic | 8 | 2022 | 413 | 0.280 |
Why?
| | Signal Transduction | 3 | 2021 | 5226 | 0.280 |
Why?
| | Administration, Intravaginal | 2 | 2020 | 19 | 0.280 |
Why?
| | Bone Remodeling | 2 | 2008 | 71 | 0.280 |
Why?
| | Ovariectomy | 3 | 2023 | 166 | 0.270 |
Why?
| | Carotid Artery Diseases | 2 | 2020 | 70 | 0.270 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 58 | 0.270 |
Why?
| | Magnetic Resonance Imaging | 4 | 2026 | 3916 | 0.270 |
Why?
| | Vitamin D Deficiency | 2 | 2021 | 190 | 0.270 |
Why?
| | Mentors | 1 | 2010 | 217 | 0.270 |
Why?
| | Mood Disorders | 3 | 2015 | 144 | 0.270 |
Why?
| | Oocyte Retrieval | 3 | 2015 | 17 | 0.260 |
Why?
| | Polyps | 1 | 2007 | 14 | 0.260 |
Why?
| | Breast Neoplasms | 4 | 2022 | 2393 | 0.260 |
Why?
| | Metformin | 3 | 2012 | 329 | 0.260 |
Why?
| | Adaptation, Psychological | 3 | 2018 | 719 | 0.260 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2023 | 265 | 0.260 |
Why?
| | Models, Biological | 6 | 2025 | 1764 | 0.250 |
Why?
| | Risk Assessment | 12 | 2024 | 3752 | 0.250 |
Why?
| | Pericardium | 3 | 2019 | 59 | 0.250 |
Why?
| | Virilism | 1 | 2007 | 6 | 0.250 |
Why?
| | Vitamin D | 3 | 2021 | 404 | 0.250 |
Why?
| | Antioxidants | 2 | 2021 | 550 | 0.250 |
Why?
| | Dehydroepiandrosterone Sulfate | 6 | 2011 | 43 | 0.250 |
Why?
| | Pituitary-Adrenal System | 3 | 2017 | 164 | 0.250 |
Why?
| | Fertilization | 3 | 2022 | 43 | 0.240 |
Why?
| | Reproductive Techniques | 3 | 2001 | 5 | 0.240 |
Why?
| | Attitude to Health | 3 | 2009 | 430 | 0.240 |
Why?
| | Child | 24 | 2024 | 22740 | 0.240 |
Why?
| | Insulin-Like Growth Factor I | 5 | 2022 | 317 | 0.230 |
Why?
| | Autoimmunity | 2 | 2024 | 933 | 0.230 |
Why?
| | Metabolome | 1 | 2009 | 391 | 0.230 |
Why?
| | Specimen Handling | 3 | 2018 | 183 | 0.230 |
Why?
| | Affect | 3 | 2018 | 321 | 0.230 |
Why?
| | Reference Values | 9 | 2020 | 798 | 0.230 |
Why?
| | New York City | 6 | 2010 | 85 | 0.230 |
Why?
| | Leuprolide | 4 | 1998 | 21 | 0.230 |
Why?
| | Glucose | 3 | 2024 | 1050 | 0.230 |
Why?
| | Cholesterol, LDL | 2 | 2010 | 360 | 0.220 |
Why?
| | Pilot Projects | 5 | 2020 | 1898 | 0.220 |
Why?
| | Atrophy | 2 | 2020 | 199 | 0.220 |
Why?
| | Contraceptive Agents, Female | 2 | 2016 | 80 | 0.220 |
Why?
| | Infant, Newborn | 10 | 2024 | 6465 | 0.220 |
Why?
| | Dehydroepiandrosterone | 5 | 2016 | 49 | 0.220 |
Why?
| | Case-Control Studies | 7 | 2020 | 3634 | 0.220 |
Why?
| | Recovery of Function | 2 | 2008 | 716 | 0.210 |
Why?
| | Follistatin | 1 | 2004 | 12 | 0.210 |
Why?
| | Biology | 2 | 2023 | 89 | 0.210 |
Why?
| | Bariatric Surgery | 1 | 2008 | 253 | 0.210 |
Why?
| | Blood Pressure | 5 | 2026 | 1782 | 0.210 |
Why?
| | Vascular Calcification | 2 | 2019 | 110 | 0.210 |
Why?
| | Pituitary Hormones, Anterior | 1 | 2024 | 7 | 0.210 |
Why?
| | Lipolysis | 1 | 2024 | 44 | 0.210 |
Why?
| | Ideal Body Weight | 1 | 2024 | 4 | 0.210 |
Why?
| | C-Reactive Protein | 4 | 2022 | 423 | 0.210 |
Why?
| | Oxidative Stress | 2 | 2021 | 1361 | 0.210 |
Why?
| | Age of Onset | 3 | 2017 | 557 | 0.210 |
Why?
| | Environmental Pollutants | 1 | 2026 | 139 | 0.210 |
Why?
| | Socioeconomic Factors | 7 | 2013 | 1327 | 0.210 |
Why?
| | Thyroid Gland | 1 | 2024 | 91 | 0.210 |
Why?
| | Ovum | 1 | 2024 | 30 | 0.210 |
Why?
| | Physical Conditioning, Human | 1 | 2024 | 38 | 0.210 |
Why?
| | Alanine Transaminase | 1 | 2024 | 151 | 0.200 |
Why?
| | Embryo Culture Techniques | 1 | 2024 | 11 | 0.200 |
Why?
| | Positron-Emission Tomography | 1 | 2026 | 343 | 0.200 |
Why?
| | Diet, Fat-Restricted | 1 | 2024 | 79 | 0.200 |
Why?
| | Academic Medical Centers | 4 | 2021 | 554 | 0.200 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 3937 | 0.200 |
Why?
| | Pediatric Obesity | 2 | 2024 | 638 | 0.200 |
Why?
| | Skin Aging | 2 | 2016 | 22 | 0.200 |
Why?
| | Focus Groups | 2 | 2024 | 572 | 0.200 |
Why?
| | Quality-Adjusted Life Years | 1 | 2024 | 125 | 0.200 |
Why?
| | Blood Glucose | 7 | 2025 | 2344 | 0.200 |
Why?
| | Neoplasms | 4 | 2024 | 2913 | 0.200 |
Why?
| | Glucose Intolerance | 1 | 2024 | 142 | 0.190 |
Why?
| | Endometrial Hyperplasia | 1 | 2023 | 6 | 0.190 |
Why?
| | Bone Resorption | 2 | 2015 | 81 | 0.190 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 1062 | 0.190 |
Why?
| | Gastrointestinal Microbiome | 2 | 2022 | 768 | 0.190 |
Why?
| | Drug Therapy, Combination | 5 | 2018 | 1043 | 0.190 |
Why?
| | Oligomenorrhea | 2 | 2014 | 10 | 0.190 |
Why?
| | Animals | 16 | 2026 | 38106 | 0.190 |
Why?
| | Amyloid beta-Peptides | 1 | 2026 | 246 | 0.190 |
Why?
| | National Institute of Child Health and Human Development (U.S.) | 2 | 2023 | 8 | 0.190 |
Why?
| | Dyspareunia | 2 | 2016 | 8 | 0.190 |
Why?
| | Ovulation Detection | 1 | 2002 | 1 | 0.190 |
Why?
| | Fractures, Bone | 2 | 2008 | 428 | 0.190 |
Why?
| | Cell Cycle Proteins | 1 | 2007 | 630 | 0.190 |
Why?
| | Insulin-Like Growth Factor Binding Protein 1 | 2 | 2019 | 25 | 0.190 |
Why?
| | Interleukin-6 | 2 | 2022 | 780 | 0.190 |
Why?
| | Asymptomatic Diseases | 3 | 2018 | 104 | 0.180 |
Why?
| | Dilatation and Curettage | 2 | 2021 | 13 | 0.180 |
Why?
| | Carotid Stenosis | 1 | 2024 | 107 | 0.180 |
Why?
| | Reimbursement Mechanisms | 2 | 2001 | 79 | 0.180 |
Why?
| | Brachial Artery | 2 | 2026 | 208 | 0.180 |
Why?
| | Simvastatin | 1 | 2002 | 59 | 0.180 |
Why?
| | Smoking | 6 | 2015 | 1477 | 0.180 |
Why?
| | Cuba | 3 | 2010 | 15 | 0.180 |
Why?
| | Retrospective Studies | 14 | 2024 | 17330 | 0.180 |
Why?
| | Central America | 3 | 2010 | 28 | 0.180 |
Why?
| | Fatty Liver | 1 | 2024 | 253 | 0.180 |
Why?
| | South America | 3 | 2010 | 56 | 0.180 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 80 | 0.170 |
Why?
| | Puerto Rico | 3 | 2010 | 63 | 0.170 |
Why?
| | Germ Cells | 1 | 2022 | 66 | 0.170 |
Why?
| | Washington | 1 | 2022 | 149 | 0.170 |
Why?
| | Goals | 1 | 2023 | 185 | 0.170 |
Why?
| | Ankle Brachial Index | 1 | 2021 | 41 | 0.170 |
Why?
| | Semen Analysis | 4 | 2022 | 15 | 0.170 |
Why?
| | Health Behavior | 1 | 2007 | 791 | 0.170 |
Why?
| | Urologic Surgical Procedures, Male | 2 | 2011 | 35 | 0.170 |
Why?
| | Inflammation Mediators | 1 | 2024 | 507 | 0.170 |
Why?
| | Vascular Stiffness | 1 | 2026 | 487 | 0.170 |
Why?
| | Anti-HIV Agents | 2 | 2005 | 912 | 0.170 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 32 | 0.170 |
Why?
| | Emulsions | 1 | 2021 | 59 | 0.170 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2021 | 29 | 0.170 |
Why?
| | Referral and Consultation | 3 | 2016 | 869 | 0.160 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 261 | 0.160 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 644 | 0.160 |
Why?
| | Linear Models | 7 | 2019 | 849 | 0.160 |
Why?
| | Sexual Behavior | 3 | 2016 | 495 | 0.160 |
Why?
| | Pulse Wave Analysis | 1 | 2021 | 267 | 0.160 |
Why?
| | Thinness | 1 | 2021 | 100 | 0.160 |
Why?
| | Genetic Fitness | 1 | 2021 | 57 | 0.160 |
Why?
| | Endometrial Neoplasms | 1 | 2023 | 205 | 0.160 |
Why?
| | Glucose Clamp Technique | 1 | 2021 | 199 | 0.160 |
Why?
| | Cell Proliferation | 2 | 2009 | 2514 | 0.160 |
Why?
| | Heat-Shock Proteins | 1 | 2021 | 139 | 0.160 |
Why?
| | Dominican Republic | 2 | 2010 | 29 | 0.160 |
Why?
| | Vasodilation | 2 | 2026 | 521 | 0.160 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2021 | 118 | 0.160 |
Why?
| | Patient Reported Outcome Measures | 2 | 2024 | 498 | 0.160 |
Why?
| | Coitus | 2 | 2022 | 24 | 0.150 |
Why?
| | Drug Combinations | 3 | 2016 | 396 | 0.150 |
Why?
| | Spermatozoa | 3 | 2022 | 107 | 0.150 |
Why?
| | Vitamins | 1 | 2021 | 184 | 0.150 |
Why?
| | Electronics | 1 | 2000 | 65 | 0.150 |
Why?
| | Down-Regulation | 5 | 2019 | 618 | 0.150 |
Why?
| | Choice Behavior | 1 | 2021 | 180 | 0.150 |
Why?
| | Biomarkers, Tumor | 1 | 2007 | 1329 | 0.150 |
Why?
| | Hypertension | 2 | 2024 | 1276 | 0.150 |
Why?
| | Gene Expression | 3 | 2021 | 1478 | 0.150 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 188 | 0.150 |
Why?
| | Growth Hormone | 2 | 2022 | 91 | 0.150 |
Why?
| | RNA, Messenger | 6 | 2011 | 2805 | 0.150 |
Why?
| | Puberty | 2 | 2019 | 137 | 0.150 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2011 | 41 | 0.150 |
Why?
| | Lipoproteins, HDL | 3 | 2015 | 100 | 0.150 |
Why?
| | Ethics, Medical | 1 | 2000 | 91 | 0.150 |
Why?
| | Gonadotropins, Pituitary | 4 | 2011 | 22 | 0.150 |
Why?
| | Pre-Eclampsia | 2 | 2018 | 206 | 0.150 |
Why?
| | Leptin | 3 | 2022 | 248 | 0.150 |
Why?
| | Acculturation | 2 | 2010 | 55 | 0.150 |
Why?
| | Erectile Dysfunction | 1 | 2019 | 38 | 0.150 |
Why?
| | Sulfonamides | 1 | 2023 | 583 | 0.150 |
Why?
| | Cell Nucleolus | 2 | 2010 | 20 | 0.150 |
Why?
| | Adiponectin | 3 | 2022 | 242 | 0.140 |
Why?
| | Decidua | 1 | 2019 | 22 | 0.140 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2015 | 910 | 0.140 |
Why?
| | Sperm Count | 4 | 2022 | 22 | 0.140 |
Why?
| | Spermatogenesis | 1 | 2019 | 91 | 0.140 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 13 | 0.140 |
Why?
| | Carotid Arteries | 1 | 2020 | 208 | 0.140 |
Why?
| | Surgeons | 1 | 2023 | 340 | 0.140 |
Why?
| | Allostasis | 1 | 2018 | 17 | 0.140 |
Why?
| | Ovarian Diseases | 3 | 1993 | 14 | 0.140 |
Why?
| | Ethics Committees, Research | 1 | 2018 | 41 | 0.140 |
Why?
| | Waist Circumference | 5 | 2022 | 143 | 0.140 |
Why?
| | Adrenal Glands | 1 | 1998 | 76 | 0.140 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 444 | 0.140 |
Why?
| | Genitalia | 1 | 2018 | 33 | 0.130 |
Why?
| | Feeding Behavior | 1 | 2024 | 692 | 0.130 |
Why?
| | Child Behavior | 1 | 2020 | 236 | 0.130 |
Why?
| | Periodicity | 8 | 2016 | 58 | 0.130 |
Why?
| | Placebos | 2 | 2015 | 193 | 0.130 |
Why?
| | Keratin-18 | 1 | 2017 | 12 | 0.130 |
Why?
| | Religion | 1 | 2018 | 65 | 0.130 |
Why?
| | Precision Medicine | 1 | 2022 | 461 | 0.130 |
Why?
| | Decision Support Techniques | 1 | 2022 | 480 | 0.130 |
Why?
| | Phytotherapy | 1 | 2017 | 74 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 751 | 0.130 |
Why?
| | Clinical Protocols | 1 | 2018 | 280 | 0.120 |
Why?
| | Comorbidity | 5 | 2014 | 1662 | 0.120 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2017 | 38 | 0.120 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2017 | 31 | 0.120 |
Why?
| | Receptors, Leptin | 2 | 2013 | 25 | 0.120 |
Why?
| | Body Weight | 4 | 2015 | 972 | 0.120 |
Why?
| | Microbiota | 1 | 2024 | 730 | 0.120 |
Why?
| | Vaginal Creams, Foams, and Jellies | 1 | 2016 | 4 | 0.120 |
Why?
| | Orgasm | 1 | 2016 | 6 | 0.120 |
Why?
| | Heart | 1 | 2020 | 626 | 0.120 |
Why?
| | Disease Progression | 4 | 2020 | 2865 | 0.120 |
Why?
| | Regional Blood Flow | 1 | 2018 | 514 | 0.120 |
Why?
| | Oxytocics | 1 | 2016 | 15 | 0.120 |
Why?
| | Antidepressive Agents | 1 | 2018 | 242 | 0.120 |
Why?
| | Evidence-Based Practice | 1 | 2018 | 231 | 0.120 |
Why?
| | Societies, Scientific | 1 | 2016 | 50 | 0.120 |
Why?
| | Endocrine System Diseases | 1 | 2016 | 35 | 0.120 |
Why?
| | Autoantibodies | 2 | 2024 | 1509 | 0.110 |
Why?
| | Fluoroimmunoassay | 2 | 1999 | 4 | 0.110 |
Why?
| | Confidence Intervals | 4 | 2011 | 330 | 0.110 |
Why?
| | Causality | 2 | 2014 | 127 | 0.110 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 165 | 0.110 |
Why?
| | Antineoplastic Agents | 2 | 2024 | 2219 | 0.110 |
Why?
| | Health Status | 3 | 2023 | 835 | 0.110 |
Why?
| | Oxytocin | 1 | 2016 | 51 | 0.110 |
Why?
| | Hirsutism | 2 | 2017 | 12 | 0.110 |
Why?
| | Chlamydia trachomatis | 1 | 2015 | 49 | 0.110 |
Why?
| | Mutation | 4 | 2013 | 4090 | 0.110 |
Why?
| | Intrauterine Devices, Medicated | 1 | 2015 | 27 | 0.110 |
Why?
| | Body Constitution | 3 | 2004 | 51 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1777 | 0.110 |
Why?
| | Observational Studies as Topic | 1 | 2016 | 134 | 0.110 |
Why?
| | Mobility Limitation | 1 | 2015 | 67 | 0.110 |
Why?
| | Chromatography, Liquid | 2 | 2015 | 450 | 0.110 |
Why?
| | Conserved Sequence | 1 | 1996 | 244 | 0.110 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1430 | 0.110 |
Why?
| | Sequence Alignment | 1 | 1996 | 362 | 0.110 |
Why?
| | Stress, Physiological | 1 | 2018 | 443 | 0.110 |
Why?
| | Child Development | 1 | 2020 | 483 | 0.110 |
Why?
| | Patient Dropouts | 1 | 2015 | 66 | 0.110 |
Why?
| | Drug Approval | 1 | 2015 | 93 | 0.110 |
Why?
| | Fetal Growth Retardation | 2 | 2019 | 593 | 0.110 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2015 | 66 | 0.110 |
Why?
| | Societies, Medical | 3 | 2017 | 900 | 0.110 |
Why?
| | Antibodies, Bacterial | 1 | 2015 | 147 | 0.110 |
Why?
| | Infant | 15 | 2024 | 10091 | 0.110 |
Why?
| | Interferon-alpha | 1 | 1996 | 193 | 0.110 |
Why?
| | Limit of Detection | 1 | 2015 | 92 | 0.110 |
Why?
| | Contraindications | 1 | 2014 | 90 | 0.110 |
Why?
| | Survival Analysis | 4 | 2014 | 1378 | 0.110 |
Why?
| | Chlamydia Infections | 1 | 2015 | 79 | 0.110 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 306 | 0.110 |
Why?
| | Algorithms | 4 | 2011 | 1851 | 0.110 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 208 | 0.110 |
Why?
| | Adaptation, Physiological | 1 | 2018 | 560 | 0.100 |
Why?
| | Migraine Disorders | 1 | 2016 | 114 | 0.100 |
Why?
| | Self Report | 4 | 2026 | 876 | 0.100 |
Why?
| | Physical Fitness | 1 | 2015 | 207 | 0.100 |
Why?
| | Cellular Microenvironment | 1 | 2015 | 94 | 0.100 |
Why?
| | Immunoglobulin G | 2 | 2015 | 892 | 0.100 |
Why?
| | Arthritis, Psoriatic | 1 | 2014 | 15 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1217 | 0.100 |
Why?
| | Core Binding Factors | 1 | 2013 | 2 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 337 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2009 | 1969 | 0.100 |
Why?
| | Sperm Motility | 3 | 2022 | 37 | 0.100 |
Why?
| | Laparoscopy | 1 | 2018 | 481 | 0.100 |
Why?
| | Air Pollution | 1 | 2017 | 315 | 0.100 |
Why?
| | Creatinine | 3 | 2022 | 515 | 0.100 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 2123 | 0.100 |
Why?
| | Oocytes | 2 | 2011 | 185 | 0.100 |
Why?
| | Cluster Analysis | 1 | 2015 | 501 | 0.100 |
Why?
| | Bone Marrow Transplantation | 4 | 1999 | 298 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2013 | 72 | 0.100 |
Why?
| | Brain | 1 | 2026 | 2969 | 0.100 |
Why?
| | Fatigue | 1 | 2015 | 366 | 0.100 |
Why?
| | Range of Motion, Articular | 1 | 2015 | 429 | 0.100 |
Why?
| | Electronic Health Records | 1 | 2021 | 1202 | 0.090 |
Why?
| | Child, Preschool | 16 | 2020 | 11868 | 0.090 |
Why?
| | Nerve Tissue Proteins | 3 | 2011 | 592 | 0.090 |
Why?
| | Muscle Strength | 1 | 2015 | 332 | 0.090 |
Why?
| | Contraceptives, Oral | 2 | 2003 | 37 | 0.090 |
Why?
| | Chi-Square Distribution | 4 | 2015 | 528 | 0.090 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2012 | 6 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2015 | 8347 | 0.090 |
Why?
| | Drug Administration Schedule | 2 | 2012 | 782 | 0.090 |
Why?
| | Anxiety Disorders | 1 | 2015 | 371 | 0.090 |
Why?
| | Rats | 3 | 2019 | 5585 | 0.090 |
Why?
| | Heart Diseases | 1 | 2015 | 341 | 0.090 |
Why?
| | Methadone | 2 | 2011 | 123 | 0.090 |
Why?
| | Varicocele | 1 | 2011 | 12 | 0.090 |
Why?
| | Heart Rate | 1 | 2016 | 856 | 0.090 |
Why?
| | China | 4 | 2011 | 274 | 0.090 |
Why?
| | Models, Theoretical | 1 | 2015 | 560 | 0.090 |
Why?
| | Placenta Diseases | 1 | 2011 | 20 | 0.090 |
Why?
| | Tissue Banks | 1 | 2011 | 17 | 0.090 |
Why?
| | Receptors, Somatomedin | 1 | 2011 | 5 | 0.090 |
Why?
| | Receptors, Glucagon | 1 | 2011 | 27 | 0.090 |
Why?
| | Somatomedins | 1 | 2011 | 28 | 0.090 |
Why?
| | Epithelial Cells | 2 | 2009 | 1135 | 0.090 |
Why?
| | Siblings | 2 | 2009 | 196 | 0.090 |
Why?
| | Receptor, trkA | 1 | 2011 | 18 | 0.080 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2601 | 0.080 |
Why?
| | Skin | 1 | 2016 | 754 | 0.080 |
Why?
| | Narcotics | 1 | 2011 | 58 | 0.080 |
Why?
| | Promoter Regions, Genetic | 1 | 1996 | 1247 | 0.080 |
Why?
| | Protease Inhibitors | 1 | 2011 | 102 | 0.080 |
Why?
| | CD4 Lymphocyte Count | 3 | 2006 | 280 | 0.080 |
Why?
| | Glucagon | 1 | 2011 | 114 | 0.080 |
Why?
| | Skin Physiological Phenomena | 1 | 2010 | 24 | 0.080 |
Why?
| | Pelvic Organ Prolapse | 1 | 2011 | 62 | 0.080 |
Why?
| | Actigraphy | 3 | 2017 | 148 | 0.080 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2010 | 15 | 0.080 |
Why?
| | Superovulation | 3 | 2012 | 8 | 0.080 |
Why?
| | Hip Fractures | 1 | 2011 | 87 | 0.080 |
Why?
| | Decision Trees | 1 | 2010 | 78 | 0.080 |
Why?
| | Waist-Hip Ratio | 2 | 2026 | 37 | 0.080 |
Why?
| | Japan | 3 | 2011 | 149 | 0.080 |
Why?
| | Transcription, Genetic | 2 | 1997 | 1454 | 0.080 |
Why?
| | Environment | 2 | 2003 | 293 | 0.080 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2011 | 376 | 0.080 |
Why?
| | Fetal Diseases | 1 | 2011 | 194 | 0.080 |
Why?
| | Career Mobility | 1 | 2010 | 68 | 0.080 |
Why?
| | Minisatellite Repeats | 1 | 2009 | 36 | 0.080 |
Why?
| | Lithium Chloride | 1 | 2009 | 14 | 0.070 |
Why?
| | Glucocorticoids | 1 | 1993 | 532 | 0.070 |
Why?
| | Quality Control | 2 | 2000 | 161 | 0.070 |
Why?
| | HIV Seropositivity | 2 | 2011 | 119 | 0.070 |
Why?
| | Blastocyst | 1 | 2009 | 50 | 0.070 |
Why?
| | Health Promotion | 1 | 2015 | 775 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 251 | 0.070 |
Why?
| | Comprehension | 1 | 2011 | 187 | 0.070 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 2 | 1999 | 15 | 0.070 |
Why?
| | Proteomics | 1 | 2015 | 1188 | 0.070 |
Why?
| | Vaginitis | 1 | 2008 | 2 | 0.070 |
Why?
| | Perception | 1 | 2011 | 378 | 0.070 |
Why?
| | Memory | 1 | 2011 | 297 | 0.070 |
Why?
| | Nuclear Pore | 1 | 2008 | 19 | 0.070 |
Why?
| | Osteoprotegerin | 1 | 2008 | 22 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 2028 | 0.070 |
Why?
| | Sleep Apnea Syndromes | 1 | 2009 | 98 | 0.070 |
Why?
| | Embryo Implantation | 1 | 2008 | 34 | 0.070 |
Why?
| | Birth Weight | 2 | 2024 | 517 | 0.070 |
Why?
| | Uterine Prolapse | 1 | 2008 | 14 | 0.070 |
Why?
| | Analysis of Variance | 4 | 2019 | 1300 | 0.070 |
Why?
| | Coronary Disease | 2 | 2012 | 382 | 0.070 |
Why?
| | Androstenedione | 2 | 1999 | 10 | 0.070 |
Why?
| | Infant, Low Birth Weight | 2 | 2019 | 156 | 0.070 |
Why?
| | Autoimmune Diseases | 2 | 2003 | 469 | 0.070 |
Why?
| | Anthropometry | 1 | 2008 | 206 | 0.070 |
Why?
| | Social Class | 1 | 2009 | 264 | 0.060 |
Why?
| | Data Collection | 1 | 2010 | 643 | 0.060 |
Why?
| | Skin Absorption | 1 | 2007 | 14 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2015 | 963 | 0.060 |
Why?
| | Combined Modality Therapy | 5 | 2021 | 1271 | 0.060 |
Why?
| | Tissue Distribution | 1 | 2007 | 335 | 0.060 |
Why?
| | Receptors, Steroid | 1 | 2007 | 42 | 0.060 |
Why?
| | Cultural Characteristics | 1 | 2007 | 69 | 0.060 |
Why?
| | Interpersonal Relations | 1 | 2010 | 400 | 0.060 |
Why?
| | Hypoglycemia | 1 | 2011 | 480 | 0.060 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2013 | 688 | 0.060 |
Why?
| | Administration, Topical | 1 | 2007 | 155 | 0.060 |
Why?
| | Research Design | 2 | 2011 | 1139 | 0.060 |
Why?
| | Asparaginase | 3 | 2001 | 32 | 0.060 |
Why?
| | Relaxin | 2 | 1998 | 18 | 0.060 |
Why?
| | Proteins | 3 | 1989 | 1023 | 0.060 |
Why?
| | Patient Satisfaction | 2 | 2021 | 712 | 0.060 |
Why?
| | Age Distribution | 2 | 2004 | 404 | 0.060 |
Why?
| | Gonadal Hormones | 1 | 2005 | 5 | 0.060 |
Why?
| | Phthalic Acids | 1 | 2026 | 42 | 0.060 |
Why?
| | Phosphorylation | 2 | 2021 | 1708 | 0.060 |
Why?
| | Lipid Metabolism | 1 | 2009 | 529 | 0.060 |
Why?
| | Tissue Donors | 1 | 2009 | 420 | 0.060 |
Why?
| | Interleukin-1 | 1 | 2009 | 961 | 0.060 |
Why?
| | Entropy | 1 | 2025 | 44 | 0.060 |
Why?
| | Preoptic Area | 1 | 2005 | 8 | 0.060 |
Why?
| | Inhibin-beta Subunits | 1 | 2005 | 6 | 0.060 |
Why?
| | Spouses | 1 | 2007 | 109 | 0.060 |
Why?
| | Maternal Age | 2 | 2022 | 128 | 0.060 |
Why?
| | Anorexia Nervosa | 1 | 2006 | 79 | 0.060 |
Why?
| | Phenols | 1 | 2026 | 106 | 0.060 |
Why?
| | Libido | 1 | 2005 | 24 | 0.060 |
Why?
| | Stochastic Processes | 1 | 2025 | 65 | 0.060 |
Why?
| | Health Services Misuse | 1 | 2005 | 35 | 0.060 |
Why?
| | Mathematical Concepts | 1 | 2025 | 35 | 0.060 |
Why?
| | Population Surveillance | 1 | 2008 | 484 | 0.050 |
Why?
| | Blastomeres | 1 | 2004 | 11 | 0.050 |
Why?
| | Iodide Peroxidase | 1 | 2024 | 35 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 1 | 2014 | 1180 | 0.050 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 264 | 0.050 |
Why?
| | Internet | 2 | 2015 | 693 | 0.050 |
Why?
| | Fluorocarbons | 1 | 2026 | 120 | 0.050 |
Why?
| | Apoptosis | 2 | 2017 | 2445 | 0.050 |
Why?
| | Nuclear Proteins | 3 | 2022 | 740 | 0.050 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2017 | 533 | 0.050 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 2 | 2001 | 32 | 0.050 |
Why?
| | Absorptiometry, Photon | 3 | 2015 | 277 | 0.050 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2025 | 156 | 0.050 |
Why?
| | Infusions, Intravenous | 3 | 1994 | 428 | 0.050 |
Why?
| | Vulnerable Populations | 1 | 2005 | 176 | 0.050 |
Why?
| | Bone Marrow | 1 | 2005 | 307 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 1330 | 0.050 |
Why?
| | Fetal Macrosomia | 1 | 2024 | 63 | 0.050 |
Why?
| | Central Nervous System | 1 | 2005 | 282 | 0.050 |
Why?
| | Sex Characteristics | 3 | 2019 | 789 | 0.050 |
Why?
| | MicroRNAs | 1 | 2009 | 686 | 0.050 |
Why?
| | Glutamic Acid | 1 | 2005 | 255 | 0.050 |
Why?
| | Minority Groups | 1 | 2005 | 285 | 0.050 |
Why?
| | Elasticity | 2 | 2016 | 189 | 0.050 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 195 | 0.050 |
Why?
| | Sugars | 1 | 2023 | 40 | 0.050 |
Why?
| | Mice | 5 | 2026 | 18358 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 979 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2023 | 148 | 0.050 |
Why?
| | Melphalan | 2 | 1999 | 43 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 2022 | 15 | 0.050 |
Why?
| | Mass Screening | 1 | 2011 | 1361 | 0.050 |
Why?
| | Follicular Atresia | 1 | 2002 | 4 | 0.050 |
Why?
| | Remission Induction | 4 | 2009 | 306 | 0.040 |
Why?
| | alpha-Amylases | 1 | 2022 | 11 | 0.040 |
Why?
| | Whole-Body Irradiation | 2 | 1999 | 74 | 0.040 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2002 | 67 | 0.040 |
Why?
| | Snoring | 1 | 2021 | 19 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2004 | 404 | 0.040 |
Why?
| | Thyroid Hormones | 1 | 2022 | 69 | 0.040 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 32 | 0.040 |
Why?
| | Breast | 1 | 2022 | 156 | 0.040 |
Why?
| | Computers | 2 | 2000 | 66 | 0.040 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2022 | 88 | 0.040 |
Why?
| | Maternal-Child Nursing | 1 | 2001 | 10 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2770 | 0.040 |
Why?
| | Nursing Methodology Research | 1 | 2001 | 43 | 0.040 |
Why?
| | Executive Function | 1 | 2026 | 470 | 0.040 |
Why?
| | Prevotella | 1 | 2021 | 26 | 0.040 |
Why?
| | X Chromosome | 1 | 2001 | 66 | 0.040 |
Why?
| | Radiography | 2 | 2014 | 853 | 0.040 |
Why?
| | Anger | 1 | 2001 | 61 | 0.040 |
Why?
| | Open Reading Frames | 1 | 2021 | 130 | 0.040 |
Why?
| | Pulmonary Blastoma | 1 | 2000 | 8 | 0.040 |
Why?
| | Canada | 1 | 2022 | 432 | 0.040 |
Why?
| | Body Surface Area | 1 | 2020 | 34 | 0.040 |
Why?
| | Grief | 1 | 2001 | 51 | 0.040 |
Why?
| | Heparin | 1 | 2022 | 247 | 0.040 |
Why?
| | Insemination | 1 | 2020 | 1 | 0.040 |
Why?
| | Illinois | 1 | 2020 | 49 | 0.040 |
Why?
| | Blood Volume | 1 | 2020 | 65 | 0.040 |
Why?
| | Paper | 1 | 2000 | 9 | 0.040 |
Why?
| | Pleural Neoplasms | 1 | 2000 | 31 | 0.040 |
Why?
| | Chicago | 1 | 2020 | 62 | 0.040 |
Why?
| | Gestures | 1 | 2020 | 7 | 0.040 |
Why?
| | Cell Line | 2 | 2021 | 2823 | 0.040 |
Why?
| | Gestational Age | 1 | 2024 | 990 | 0.040 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 1999 | 6 | 0.040 |
Why?
| | Reproducibility of Results | 3 | 2018 | 3418 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2014 | 971 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2024 | 521 | 0.040 |
Why?
| | Personal Autonomy | 1 | 2000 | 61 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 757 | 0.040 |
Why?
| | Observer Variation | 1 | 2000 | 357 | 0.040 |
Why?
| | Thrombin | 1 | 2000 | 172 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2026 | 956 | 0.040 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 1999 | 74 | 0.040 |
Why?
| | Sexual Maturation | 1 | 2019 | 48 | 0.040 |
Why?
| | Base Sequence | 3 | 2001 | 2171 | 0.040 |
Why?
| | Alzheimer Disease | 1 | 2026 | 630 | 0.040 |
Why?
| | Gene Deletion | 1 | 2001 | 392 | 0.040 |
Why?
| | Sex Factors | 2 | 2019 | 2110 | 0.040 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 1999 | 5 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 295 | 0.040 |
Why?
| | Triglycerides | 2 | 2017 | 520 | 0.040 |
Why?
| | Chromosome Breakage | 1 | 1999 | 23 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 1999 | 36 | 0.040 |
Why?
| | Chromosome Inversion | 1 | 1999 | 20 | 0.040 |
Why?
| | Sensitivity and Specificity | 3 | 2008 | 2000 | 0.040 |
Why?
| | Educational Status | 2 | 2012 | 470 | 0.040 |
Why?
| | Energy Metabolism | 2 | 2022 | 935 | 0.040 |
Why?
| | Italy | 3 | 2009 | 117 | 0.030 |
Why?
| | Diet | 2 | 2023 | 1278 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 508 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2001 | 2883 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2021 | 473 | 0.030 |
Why?
| | Hyperthyroidism | 1 | 2018 | 22 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 452 | 0.030 |
Why?
| | Genetic Testing | 1 | 2001 | 483 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 364 | 0.030 |
Why?
| | Injections, Intravenous | 2 | 1990 | 197 | 0.030 |
Why?
| | Insurance, Health | 1 | 2001 | 311 | 0.030 |
Why?
| | Microinjections | 1 | 1998 | 92 | 0.030 |
Why?
| | Needs Assessment | 1 | 2001 | 403 | 0.030 |
Why?
| | Diagnostic Techniques, Obstetrical and Gynecological | 2 | 2008 | 7 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2019 | 139 | 0.030 |
Why?
| | Glucuronates | 1 | 2017 | 5 | 0.030 |
Why?
| | Neurons | 1 | 2007 | 1652 | 0.030 |
Why?
| | Organ Size | 2 | 2010 | 461 | 0.030 |
Why?
| | Transaminases | 1 | 2017 | 22 | 0.030 |
Why?
| | Conservative Treatment | 1 | 2018 | 45 | 0.030 |
Why?
| | Islets of Langerhans | 1 | 2004 | 847 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 408 | 0.030 |
Why?
| | Receptors, Angiotensin | 1 | 1997 | 11 | 0.030 |
Why?
| | Immunologic Tests | 1 | 1997 | 16 | 0.030 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 60 | 0.030 |
Why?
| | Pregnancy Tests | 1 | 2017 | 11 | 0.030 |
Why?
| | Vehicle Emissions | 1 | 2017 | 57 | 0.030 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 303 | 0.030 |
Why?
| | Biopsy | 1 | 2000 | 1082 | 0.030 |
Why?
| | Disease-Free Survival | 4 | 2001 | 770 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2021 | 584 | 0.030 |
Why?
| | Biological Assay | 1 | 2017 | 132 | 0.030 |
Why?
| | Public Health | 1 | 2022 | 574 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2933 | 0.030 |
Why?
| | Genes | 1 | 1997 | 228 | 0.030 |
Why?
| | Molecular Weight | 3 | 2013 | 312 | 0.030 |
Why?
| | Hypertriglyceridemia | 1 | 2017 | 45 | 0.030 |
Why?
| | Thrombosis | 1 | 2000 | 400 | 0.030 |
Why?
| | Transdermal Patch | 1 | 2016 | 15 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2001 | 2131 | 0.030 |
Why?
| | Hepatitis C | 2 | 2011 | 256 | 0.030 |
Why?
| | Hyperprolactinemia | 1 | 2016 | 6 | 0.030 |
Why?
| | Galvanic Skin Response | 1 | 2016 | 26 | 0.030 |
Why?
| | Goiter | 1 | 1996 | 5 | 0.030 |
Why?
| | Genes, Regulator | 1 | 1996 | 35 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2001 | 693 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 558 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 2 | 2008 | 127 | 0.030 |
Why?
| | Serologic Tests | 1 | 2015 | 54 | 0.030 |
Why?
| | Catheters, Indwelling | 2 | 1993 | 96 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2019 | 456 | 0.030 |
Why?
| | Hypothyroidism | 1 | 1996 | 68 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 428 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1996 | 387 | 0.030 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 1995 | 36 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1711 | 0.030 |
Why?
| | Genetic Markers | 2 | 2011 | 338 | 0.030 |
Why?
| | Alcohol Drinking | 2 | 2012 | 843 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1042 | 0.030 |
Why?
| | Neuroblastoma | 1 | 1996 | 174 | 0.030 |
Why?
| | Peptide Fragments | 1 | 1999 | 697 | 0.030 |
Why?
| | Cranial Irradiation | 2 | 2009 | 85 | 0.030 |
Why?
| | Neovascularization, Physiologic | 1 | 2016 | 193 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 935 | 0.030 |
Why?
| | Deafness | 1 | 1996 | 78 | 0.030 |
Why?
| | Certolizumab Pegol | 1 | 2014 | 5 | 0.030 |
Why?
| | Cyclosporine | 1 | 1995 | 256 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1512 | 0.030 |
Why?
| | Etanercept | 1 | 2014 | 60 | 0.030 |
Why?
| | Vincristine | 3 | 2001 | 144 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 1994 | 168 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1505 | 0.030 |
Why?
| | Freezing | 1 | 1994 | 83 | 0.030 |
Why?
| | Adalimumab | 1 | 2014 | 54 | 0.030 |
Why?
| | Glycerol | 1 | 1994 | 90 | 0.030 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2014 | 56 | 0.030 |
Why?
| | Drug Stability | 1 | 1994 | 169 | 0.020 |
Why?
| | Qualitative Research | 1 | 2021 | 1683 | 0.020 |
Why?
| | Anions | 1 | 2013 | 29 | 0.020 |
Why?
| | Registries | 2 | 2020 | 2410 | 0.020 |
Why?
| | Infliximab | 1 | 2014 | 111 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2014 | 162 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 849 | 0.020 |
Why?
| | Medical Records | 1 | 2014 | 192 | 0.020 |
Why?
| | Molecular Conformation | 1 | 2013 | 141 | 0.020 |
Why?
| | Carrier Proteins | 1 | 1997 | 729 | 0.020 |
Why?
| | Air Pollutants | 1 | 2017 | 407 | 0.020 |
Why?
| | Electrocardiography | 1 | 2016 | 668 | 0.020 |
Why?
| | Cell Survival | 2 | 2007 | 1105 | 0.020 |
Why?
| | Anal Canal | 1 | 1993 | 102 | 0.020 |
Why?
| | Menstruation-Inducing Agents | 1 | 2012 | 1 | 0.020 |
Why?
| | Growth Differentiation Factor 9 | 1 | 2011 | 4 | 0.020 |
Why?
| | Coffee | 1 | 2012 | 15 | 0.020 |
Why?
| | Pituitary Gland, Anterior | 1 | 2011 | 37 | 0.020 |
Why?
| | Tea | 1 | 2012 | 17 | 0.020 |
Why?
| | Women | 1 | 2012 | 47 | 0.020 |
Why?
| | Oogenesis | 1 | 2011 | 20 | 0.020 |
Why?
| | Mutation, Missense | 2 | 2006 | 335 | 0.020 |
Why?
| | Cystocele | 1 | 2011 | 1 | 0.020 |
Why?
| | Rectocele | 1 | 2011 | 4 | 0.020 |
Why?
| | Placentation | 1 | 2011 | 52 | 0.020 |
Why?
| | Fetal Death | 1 | 2011 | 58 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 159 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 36 | 0.020 |
Why?
| | Alcoholic Beverages | 1 | 2012 | 31 | 0.020 |
Why?
| | Urinary Tract Infections | 1 | 2014 | 210 | 0.020 |
Why?
| | Ulna Fractures | 1 | 2011 | 16 | 0.020 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2011 | 18 | 0.020 |
Why?
| | Nerve Growth Factor | 1 | 2011 | 36 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 203 | 0.020 |
Why?
| | Receptor, trkB | 1 | 2011 | 39 | 0.020 |
Why?
| | Progesterone Congeners | 1 | 2010 | 8 | 0.020 |
Why?
| | Heterozygote | 1 | 2011 | 314 | 0.020 |
Why?
| | Spinal Fractures | 1 | 2011 | 76 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 2010 | 165 | 0.020 |
Why?
| | Colon | 1 | 1993 | 309 | 0.020 |
Why?
| | Cross Reactions | 1 | 2010 | 130 | 0.020 |
Why?
| | Radius Fractures | 1 | 2011 | 69 | 0.020 |
Why?
| | Dominica | 1 | 2010 | 3 | 0.020 |
Why?
| | Proinsulin | 1 | 2010 | 54 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 283 | 0.020 |
Why?
| | Herpes Zoster | 1 | 2014 | 319 | 0.020 |
Why?
| | Daunorubicin | 2 | 2001 | 25 | 0.020 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2011 | 154 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2012 | 217 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2001 | 2977 | 0.020 |
Why?
| | Informed Consent | 1 | 2011 | 199 | 0.020 |
Why?
| | Hematology | 1 | 2009 | 21 | 0.020 |
Why?
| | Infusion Pumps | 1 | 1989 | 33 | 0.020 |
Why?
| | Survival Rate | 2 | 2009 | 2094 | 0.020 |
Why?
| | Pulse Therapy, Drug | 1 | 2009 | 7 | 0.020 |
Why?
| | Culture Techniques | 1 | 1989 | 66 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4556 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 1989 | 110 | 0.020 |
Why?
| | Cyclin D1 | 1 | 2009 | 64 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2009 | 74 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 649 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2009 | 83 | 0.020 |
Why?
| | Prednisone | 2 | 2001 | 226 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 170 | 0.020 |
Why?
| | West Indies | 1 | 2008 | 5 | 0.020 |
Why?
| | Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 5 | 0.020 |
Why?
| | Ambulatory Care | 1 | 1993 | 610 | 0.020 |
Why?
| | Acid Phosphatase | 1 | 2008 | 14 | 0.020 |
Why?
| | Safety | 1 | 1990 | 358 | 0.020 |
Why?
| | RANK Ligand | 1 | 2008 | 27 | 0.020 |
Why?
| | Hyperhidrosis | 1 | 2008 | 6 | 0.020 |
Why?
| | Estrogen Antagonists | 1 | 2008 | 37 | 0.020 |
Why?
| | Menorrhagia | 1 | 2008 | 22 | 0.020 |
Why?
| | Polysomnography | 1 | 2009 | 239 | 0.020 |
Why?
| | Papio | 1 | 2008 | 70 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1812 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 992 | 0.020 |
Why?
| | Pelvic Floor | 1 | 2008 | 32 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2008 | 144 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2005 | 2525 | 0.020 |
Why?
| | Isoenzymes | 1 | 2008 | 295 | 0.020 |
Why?
| | Collagen Type I | 1 | 2008 | 143 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 365 | 0.020 |
Why?
| | Microscopy, Immunoelectron | 1 | 2007 | 43 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2010 | 732 | 0.020 |
Why?
| | Transplantation, Autologous | 2 | 1999 | 301 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2007 | 138 | 0.020 |
Why?
| | Polymorphism, Genetic | 2 | 2000 | 615 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2008 | 251 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2000 | 2668 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 196 | 0.020 |
Why?
| | Transplantation Conditioning | 2 | 1999 | 191 | 0.020 |
Why?
| | Medical Oncology | 1 | 2009 | 340 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 848 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 319 | 0.020 |
Why?
| | Burkitt Lymphoma | 2 | 2000 | 61 | 0.020 |
Why?
| | New York | 1 | 2006 | 128 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2014 | 1211 | 0.010 |
Why?
| | Sleep Disorders, Intrinsic | 1 | 2005 | 1 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2011 | 1137 | 0.010 |
Why?
| | Obesity, Morbid | 1 | 2010 | 293 | 0.010 |
Why?
| | Body Fluids | 1 | 1986 | 71 | 0.010 |
Why?
| | Microdialysis | 1 | 2005 | 56 | 0.010 |
Why?
| | HIV-1 | 1 | 1991 | 908 | 0.010 |
Why?
| | Placenta | 1 | 2011 | 787 | 0.010 |
Why?
| | Phosphoproteins | 1 | 2007 | 337 | 0.010 |
Why?
| | Neoplasm, Residual | 1 | 2005 | 143 | 0.010 |
Why?
| | Stroke | 1 | 2014 | 1271 | 0.010 |
Why?
| | Urban Population | 1 | 2008 | 494 | 0.010 |
Why?
| | Demography | 1 | 2005 | 282 | 0.010 |
Why?
| | Communication | 1 | 2011 | 977 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2011 | 3130 | 0.010 |
Why?
| | Genomics | 1 | 2009 | 830 | 0.010 |
Why?
| | Life Change Events | 1 | 2005 | 147 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 2003 | 2 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1985 | 289 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1568 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2005 | 431 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 1000 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 4151 | 0.010 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2001 | 26 | 0.010 |
Why?
| | Interviews as Topic | 1 | 2005 | 916 | 0.010 |
Why?
| | Estrus | 1 | 2001 | 16 | 0.010 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 17 | 0.010 |
Why?
| | Rest | 1 | 2001 | 126 | 0.010 |
Why?
| | Calcium | 1 | 2007 | 1192 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 5995 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 2000 | 72 | 0.010 |
Why?
| | Injections, Intramuscular | 1 | 2001 | 146 | 0.010 |
Why?
| | Pedigree | 1 | 2001 | 515 | 0.010 |
Why?
| | Random Allocation | 1 | 2001 | 365 | 0.010 |
Why?
| | Transplants | 1 | 1999 | 38 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2000 | 322 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2001 | 259 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 1450 | 0.010 |
Why?
| | Consanguinity | 1 | 1999 | 49 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2001 | 268 | 0.010 |
Why?
| | Mercaptopurine | 1 | 1998 | 15 | 0.010 |
Why?
| | Thioguanine | 1 | 1998 | 18 | 0.010 |
Why?
| | Cytarabine | 1 | 1998 | 66 | 0.010 |
Why?
| | Leucovorin | 1 | 1998 | 98 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1999 | 273 | 0.010 |
Why?
| | Pregnancy Trimester, Second | 1 | 1998 | 85 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 1998 | 119 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1998 | 272 | 0.010 |
Why?
| | Chromosome Aberrations | 1 | 1998 | 166 | 0.010 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 1997 | 8 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1997 | 81 | 0.010 |
Why?
| | Dexamethasone | 1 | 1998 | 365 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1997 | 538 | 0.010 |
Why?
| | Introns | 1 | 1997 | 256 | 0.010 |
Why?
| | Doxorubicin | 1 | 1998 | 403 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1987 | 331 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 1997 | 410 | 0.010 |
Why?
| | Risk | 1 | 1998 | 923 | 0.010 |
Why?
| | Exons | 1 | 1997 | 364 | 0.010 |
Why?
| | Syndrome | 1 | 1996 | 381 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1996 | 138 | 0.010 |
Why?
| | Drug Resistance | 1 | 1995 | 145 | 0.010 |
Why?
| | Colostomy | 1 | 1993 | 28 | 0.010 |
Why?
| | Recurrence | 1 | 1996 | 1139 | 0.010 |
Why?
| | Testis | 1 | 1994 | 162 | 0.010 |
Why?
| | Liver Diseases | 1 | 1996 | 305 | 0.010 |
Why?
| | Anastomosis, Surgical | 1 | 1993 | 164 | 0.010 |
Why?
| | Lymphoma, AIDS-Related | 1 | 1991 | 14 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2000 | 2399 | 0.010 |
Why?
| | Sarcoma, Kaposi | 1 | 1991 | 83 | 0.010 |
Why?
| | Reoperation | 1 | 1993 | 637 | 0.000 |
Why?
| | Feedback | 1 | 1990 | 180 | 0.000 |
Why?
| | Equipment Contamination | 1 | 1989 | 67 | 0.000 |
Why?
| | Forearm | 1 | 1989 | 141 | 0.000 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1991 | 373 | 0.000 |
Why?
| | Bacterial Infections | 1 | 1989 | 247 | 0.000 |
Why?
| | Organ Culture Techniques | 1 | 1987 | 154 | 0.000 |
Why?
| | Isoelectric Point | 1 | 1986 | 22 | 0.000 |
Why?
| | Liver Neoplasms | 1 | 1991 | 777 | 0.000 |
Why?
| | Bacteria | 1 | 1989 | 766 | 0.000 |
Why?
| | Hemoglobins | 1 | 1986 | 386 | 0.000 |
Why?
|
|
Santoro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|